List of Jublia drug patents

Jublia is owned by Bausch.

Jublia contains Efinaconazole.

Jublia has a total of 16 drug patents out of which 0 drug patents have expired.

Jublia was authorised for market use on 06 June, 2014.

Jublia is available in solution;topical dosage forms.

Jublia can be used as topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient, topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes, antimycotic uses, specifically treatment of onychomycosis; topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes, antimycotic uses, specifically treatment of onychomycosis.

The generics of Jublia are possible to be released after 25 April, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214506 BAUSCH Method for treating onychomycosis
Feb, 2026

(3 years from now)

US11213519 BAUSCH Compositions and methods for treating diseases of the nail
Jan, 2028

(4 years from now)

US9566272 BAUSCH Compositions and methods for treating diseases of the nail
Jan, 2028

(4 years from now)

US9877955 BAUSCH Compositions and methods for treating diseases of the nail
Jan, 2028

(4 years from now)

US10512640 BAUSCH Compositions and methods for treating diseases of the nail
Jan, 2028

(4 years from now)

US10828369 BAUSCH Compositions and methods for treating diseases of the nail
Jan, 2028

(4 years from now)

US9861698 BAUSCH Compositions and methods for treating diseases of the nail
Jul, 2030

(7 years from now)

US8039494 BAUSCH Compositions and methods for treating diseases of the nail
Jul, 2030

(7 years from now)

US10105444 BAUSCH Compositions and methods for treating diseases of the nail
Jul, 2030

(7 years from now)

US9302009 BAUSCH Compositions and methods for treating diseases of the nail
Oct, 2030

(7 years from now)

US8486978 BAUSCH Compositions and methods for treating diseases of the nail
Oct, 2030

(7 years from now)

US10864274 BAUSCH Stabilized efinaconazole formulations
Oct, 2034

(11 years from now)

US9662394 BAUSCH Stabilized efinaconazole compositions
Oct, 2034

(11 years from now)

US10342875 BAUSCH Stabilized efinaconazole compositions
Oct, 2034

(11 years from now)

US10828293 BAUSCH Anti-infective methods, compositions, and devices
Oct, 2034

(11 years from now)

US10478601 BAUSCH Applicator
Apr, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of onychomycosis of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of tinea unguium by using an applicator for applying a solution for treating tinea unguium to an affected part of a patient

Dosage: SOLUTION;TOPICAL

How can I launch a generic of JUBLIA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in